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Abstract
Here, we show that SOX11, an embryonic mammary marker that is normally silent in postnatal breast cells,
is expressed in many oestrogen receptor-negative preinvasive ductal carcinoma in situ (DCIS) lesions. Mature
mammary epithelial cells engineered to express SOX11 showed alterations in progenitor cell populations, including
an expanded basal-like population with increased aldehyde dehydrogenase (ALDH) activity, and increased
mammosphere-forming capacity. DCIS.com cells engineered to express SOX11 showed increased ALDH activity,
which is a feature of cancer stem cells. The CD44+/CD24–/ALDH+ cell population was increased in DCIS.com
cells that expressed SOX11. Upregulating SOX11 expression in DCIS.com cells led to increased invasive growth
both in vitro and when they were injected intraductally in a mouse model of DCIS that recapitulates human
disease. Invasive lesions formed sooner and tumour growth was augmented in vivo, suggesting that SOX11
contributes to the progression of DCIS to invasive breast cancer. We identified potential downstream effectors
of SOX11 during both microinvasive and invasive tumour growth stages, including several with established links
to regulation of progenitor cell function and prenatal developmental growth. Our findings suggest that SOX11
is a potential biomarker for DCIS lesions containing cells harbouring distinct biological features that are likely to
progress to invasive breast cancer.
© 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Embryonic breast epithelial cells constitute a unique
cell population composed of undifferentiated and highly
plastic progenitor cells that ultimately give rise to all
other postnatal breast epithelial cells [1]. There is
increasing evidence that cancer stem or stem-like cells
exist and perpetuate the growth of cancer cells after
therapy in many solid tumours [2,3]. Cancer stem cells
identified in the skin, gut and brain are very similar
to the healthy stem cells responsible for growing and
renewing tissue in the body. Lineage-tracing studies
have indicated that embryonic mammary epithelial cells
(MECs) are multipotent in vivo [4], but their involve-
ment in breast cancer is not yet clear. Tumours may
develop from progenitor-like cells at diverse stages of
cellular differentiation [5–7], and embryonic mammary
progenitor cells have potential links to breast cancer
that remain to be explored [8].
We analysed embryonic mouse mammary gene sig-
natures, and showed remarkable similarities between
embryonic breast cells and breast cancer cells [9]. We
found that an embryonic mammary epithelial signature
was activated in mouse Brca1– /– tumours and human
basal-like breast cancers. A small network composed of
embryonic genes with known roles in progenitor/stem
cell regulation was found to be activated in some
breast cancers. One network component, SOX11, is
not detected in the normal mature postnatal breast,
and is highly expressed in basal-like and HER2+
breast cancers [9]. SOX11 is known to promote tissue
remodelling, progenitor cell expansion, and differenti-
ation of a number of cell types [10], including neural
progenitor cells [11]. Induced expression of SOX11
in embryonic stem cells [12] and embryonic kidney
cells [13] leads to induction of genes that regulate
developmental processes, including organogenesis.
SOX11 expression within preinvasive breast lesions
or invasive breast cancers may therefore indicate tis-
sues containing cells that have distinct features that
are more typically associated with prenatal mammary
progenitor cells, and patterns of growth that are differ-
ent from those characteristic of the mature postnatal
breast [14–16].
© 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
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Ductal carcinoma in situ (DCIS) presents a clinical
problem, with risk of potential over- and undertreat-
ment, and biomarkers are needed that can identify DCIS
lesions that are likely to progress and require treatment
with more aggressive therapies. SOX11 has been found
to be highly expressed in preinvasive lesions, including
DCIS [17]. Higher levels of SOX11 have been detected
in atypical ductal hyperplasia (ADH) that is associated
with breast cancer than in ADH not associated with
cancer [18]. Therefore, SOX11 is an attractive candidate
for mediating DCIS progression. Here, we analysed
the effects of upregulating SOX11 expression in both




Supplementary material, Table S1A provides details of
cell lines and media. DCIS.com-Luc cells were gener-
ated by transducing cells with lentiviral expression par-
ticles for firefly luciferase (LVP325; Amsbio, Abingdon,
UK).
Expression vectors
The SOX11 coding sequence (GENEID: 6664) from
clone HsCD00295480 [19] in the pENTR223.1
plasmid (DNASU) [20] was subcloned into the
pLenti6.3/V5-DEST Gateway vector (ThermoFisher,
Waltham, MA, USA).
Flow cytometry analyses
and fluorescence-activated cell sorting (FACS)
After trypsinization, 5 × 104 MCF10A or DCIS
.com cells expressing SOX11 or control LacZ vector
were resuspended in 100 μl of phosphate-buffered
saline (PBS) plus 10% fetal bovine serum (FBS),
and incubated with combinations of antibodies, i.e.
anti-CD49f–PE (555736) (1:100), anti-EpCAM–
PerCPCy5.5 (347199) (1:20), anti-CD24–FITC
(555427) (1:20), anti-CD24–PE–Cy7 (561646) (1:100)
and anti-CD44–APC (559942) (1:20) (BD Biosciences,
Oxford, UK) for 30 min at room temperature. Cells
were resuspended in 0.5 ml of PBS plus 10% FBS
and 4′,6-diamidino-2-phenylindole (DAPI), and filtered
through 50-μm filters. Unstained and single-antibody-
stained cells were used for compensation. By use of a
BD FACS LSRII flow cytometer, samples were analysed
with BD FACS Diva software (BD Biosciences). Alde-
hyde dehydrogenase (ALDH) activity was measured
with the Aldefluor assay (StemCell Technologies, Cam-
bridge, UK); cells were also co-stained with Aldefluor
and CD49f–PE and EpCAM–PerCPCy5.5.
Spheroid formation
Five thousand cells were plated in 96-well ultra-low-
attachment plates (Corning 7007, Corning, NY, USA),
and spheroids formed after 4 days (supplementary
material, Table S1A). Spheroid images were obtained
starting on day 4 with a Celigo cytometer (Nexcelom,
Manchester, UK).
Clonogenic assays
MCF10A cells were plated at 250 per well in six-well
(Falcon F3046, Corning, NY, USA) plates. After 7 days,
plates were stained with 0.2% crystal violet dissolved
in 20% methanol in PBS. Clones were counted, and
the percentage relative to number of cells plated was
calculated.
For mammosphere assays, 5 × 103 MCF10A cells/ml
were plated in low-attachment six-well plates (Corning
3471) and incubated in medium (supplementary mate-
rial, Table S1A) supplemented with 2% NeuroCult SM1
without vitamin A (StemCell Technologies) and 0.65%
methylcellulose (R&D Systems, Abingdon, UK). After
14 days, wells were scanned with a Celigo cytometer
(Nexcelom, Manchester, UK). Mammosphere-forming
efficiency was calculated by dividing the number of
mammospheres by the number of cells plated per well.
Immunofluorescence
Antibodies and staining protocols are detailed in sup-
plementary material, Table S1B. Images were captured
with a Leica Microsystems (Cambridge, UK) TCS-SP2
confocal microscope.
Western blotting
Western blotting was performed as previously described
[9]. Details of the antibodies used are provided in sup-
plementary material, Table S1C.
Transmigration, spheroid and invasion assays
DCIS.com cells were grown in serum-free medium for
24 h and used in Cultrex 96-well Collagen I Cell Inva-
sion Assays (Amsbio, Abingdon, UK); cells (5× 104 per
well) were plated in wells that had been coated with 1%
or 0.1% collagen, or left uncoated. Transmigration was
measured after 48 h.
Five thousand cells were plated per well in
spheroid formation ECM medium within a 96-well
three-dimensional (3D) spheroid BME cell invasion
assay (3500-096-K; Cultrex). Matrix was added 3 days
later, and culture medium was added 1 h after this
(supplementary material, Table S1A). Spheres were
measured every 2 days with a Celigo cytometer, and
images were acquired to assess spheroid morphology.
3D spheroid invasion assays were performed.
Spheroids from 5 × 103 DCIS.com cells were embed-
ded in collagen I (354249; Corning) at 2.2 mg/ml in
serum-free medium. Complete or serum-free medium
was added after 1 h. Images were acquired after 48
h with a Celigo cytometer. The total area of matrix
invaded by cells was calculated with ImageJ after
marking of the area manually.
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Proliferation and viability assays
Three thousand cells were plated in 96-well plates
(655098; Greiner Bio-one, Stonehouse, UK) for 24 h.
CellTiter-Glo (Promega, Southampton, UK) was used
according to the manufacturer’s protocol. Lumines-
cence was measured with a Victor X5 58 plate reader
(Perkin-Elmer, Seer Green, UK).
Cleaved caspase-3 (CC3) assays
Five thousand cells were plated in ultra-low-attachment
96-well plates. Five days after spheroid formation for
MCF10A cells, or 8 days after spheroid formation for
DCIS.com cells, spheroids were incubated for 1 h with
NucView-488 Caspase-3 substrate at a final concentra-
tion of 10 μM. Fluorescence was measured with the
Celigo platform.
Statistical analysis
Experiments were analysed with a two-tailed Student’s
t-test with a confidence interval of 95% when the number
of groups equalled 2, or with a parametric ANOVA and
post hoc test when the number of groups was >2, unless
otherwise specified.
Animal experiments
SCID/beige mice, purchased from Charles River (Har-
low, UK), were housed in individually ventilated cages
on a 12-h light/dark cycle, and received food and water
ad libitum. All work was carried out under UK Home
Office projects (70/7413 and 70/7712) and personal
licenses (090/02921, I5F252069, and IFFDC436E)
following receipt of local ethical approval from the
Institute of Cancer Research Ethics Committee and
in accordance with local and national guidelines. As
biological replicates, four or five mice were used.
Intraductal injections of 5 × 104 cells were performed
as previously described [21], with slight modifications,
including the chemical removal of fur, and mice not
being opened surgically. For mammary fat pad injec-
tions, 2.5 × 106 cells were injected into mammary gland
4 of 10–12-week-old female mice. Engrafted mammary
glands or tumours were harvested 6–12 weeks after
intraductal injections and 6 weeks after mammary fat
pad injections, and then fixed in formalin or snap-frozen.
RNA isolation
RNA was isolated from tumours or mammary gland
4 harbouring microinvasive lesions of each biological
replicate (n = 4–5 for each time point) with TRIzol
(Fisher Scientific, Loughborough, UK), and this was
followed by a second extraction with an RNAeasy-
Plus Micro kit (74034; Qiagen, Manchester, UK) and
DNase treatment. RNAClean and concentrator-5 (Zymo
Research, Irvine, CA, USA) were used. RNA con-
centration and purity were determined with a Qubit
fluorometer (Invitrogen, Carlsbad, CA, USA) and a
nanodrop spectrophotometer. RNA integrity number
was measured with a bioanalyser and an Agilent RNA
Pico kit (Agilent Technologies, Cheshire, UK).
cDNA synthesis
One microgram of each RNA sample was reverse tran-
scribed by use of a QuantiTect Reverse Transcription
kit (Qiagen, Manchester, UK) in a final volume of 20
μl. cDNA was diluted eight-fold for subsequent quan-
titative polymerase chain reaction (qPCR) analysis, as
described previously [9], with the probes and methods
listed in supplementary material, Table S2.
Gene expression profiling
Sequence files were trimmed by the use of trim_galore
(http://www.bioinformatics.babraham.ac.uk/projects/
trim_galore/) with default settings. Trimmed data
were separately mapped to the GRCh38 and GRCm38
genome assemblies by the use of hisat2 (v2.0.5) with
options --sp 1000,1000 -- omixed--no-discordant, and
were filtered to remove non-primary alignments.
Species-specific read sets were generated by remov-
ing any read that produced a valid alignment in both
human and mouse from the results for both species.
The remaining data were imported into SeqMonk
(http://www.bioinformatics.babraham.ac.uk/projects/
seqmonk/) with a filter of mapping quality (MAPQ)
score ≥ 20. Reads were quantified over the transcript set
from Ensembl v78 with annotated mis-spliced, pseu-
dogene and unannotated transcripts removed. Initial
quantification was raw read counts from the opposing
strand to the transcript, with all exons for each gene
being collated into a single measure. This allowed
gene-level differential expression to be assessed by
the use of DESeq2 (https://bioconductor.org/packages/
release/bioc/html/DESeq2.html), with a cutoff of a
false discovery rate of < 0.05. Subsequent visualization
was performed by requantifying expression as log2
fragments per million reads of library. RNA sequencing
data have been deposited in the European Nucleotide
Archive with the accession number PRJEB19633.
Immunohistochemistry (IHC)
IHC was performed on formalin-fixed paraffin-
embedded DCIS samples from 22 oestrogen recep-
tor (ER)+, 22 ER–, 17 HER2+ and six mixed cases
collected through the ICICLE study with appropriate
consent (MREC 08/H0502/4). Samples were stained
with two SOX11 antibodies as described previously [9]
(supplementary material, Table S3).
Scoring guidelines
The expression status of SOX11 determined with the
antibody Abcam ab170916 (Cambridge, UK) was
assessed with a semiquantitative scoring system based
on staining intensity and the proportion of positive
cells expressed as a percentage. Staining intensity was
divided into four grades (intensity scores): no stain-
ing (0), weak staining (1), moderate staining (2), and
© 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2017
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strong staining (3). The proportion of positive cells was
divided into five grades (percentage scores): <10% (0),
10–25% (1), 26–50% (2), 51–75% (3), and 76–100%
(4). SOX11 staining status was determined with the
following formula: overall score = intensity score × per-
centage score. An overall score of ≤4 was defined as low
expression; an overall score of >4 was defined as high
expression.
Survival analysis
The prognostic importance of SOX11 mRNA expression
was assessed by the use of survival data. Data obtained
from the Gene Expression Omnibus, the European
Genome-phenome Archive and The Cancer Genome
Atlas were examined by use of the Kaplan–Meier
Plotter survival analysis tool (http://kmplot.com) and
METABRIC [22], and statistical significance was
determined with the Wald test and log-rank test.
Results
Effect of SOX11 levels on postnatal mammary
progenitor cell profiles
We confirmed that SOX11 is not expressed in normal
mature breast tissue, as expected for an embryonic
mammary marker (Figure 1A). We detected SOX11
expression in triple-negative [ER–/progesterone recep-
tor (PR)–/HER2–] and HER2+ breast cancer cell lines
(Figure 1B). We did not detect significant expression
of SOX11 in DCIS.com or MCF10A cells, which
are ER– cell lines from a progression series that are
often used as models to study DCIS and normal MEC
growth, respectively (Figure 1B). To study the effects
of expressing SOX11 in a normal MEC line, we stably
transduced SOX11 into MCF10A cells (Figure 1C),
and were able to detect nuclear SOX11 expression in
MCF10A-SOX11 cells (Figure 1D).
CD49f and EpCAM expression separates distinct
subpopulations in cells isolated from human breast
epithelium [23]. Flow cytometry analysis with EpCAM
and CD49f has also identified cell subpopulations
in non-tumourigenic basal cell lines [24]. MCF10A
cells show heterogeneity, and contain two sepa-
rate subpopulations (Figure 1E): EpCAM+/CD49f
+ and EpCAM–/CD49f+. An increase in the
EpCAM–/CD49f + basal-like population was observed
among MCF10A-SOX11 cells (27.44 ± 14.58%) as
compared with MCF10A-control cells (11.38 ± 7.69%)
(Figure 1E). ALDH activity was 1.76-fold greater
in EpCAM–/CD49f + basal-like MCF10A-SOX11
cells than in MCF10A-control cells, suggesting an
expanded population associated with stem cell prop-
erties (Figure IF; supplementary material, Figure S1).
EpCAM–/CD49f+/ALDH+ cells were detected at
4.26-fold greater frequency among MCF10-SOX11
cells than among MCF10A-control cells.
Effect of SOX11 expression on postnatal MEC
growth, morphogenesis, and clonogenicity
We observed a slight but significant reduction in cell
growth in MCF10A-SOX11 cells as compared with
MCF10A-LacZ cells (Figure 2A). Morphological
differences were observed when MCF10A-SOX11
mammospheres were compared with MCF10A-LacZ
control mammospheres grown under a variety of culture
conditions; MCF10A-SOX11 mammospheres appeared
more compact and solid than controls (Figure 2B;
supplementary material, Figure S2A, B). These obser-
vations are compatible with SOX11 altering the growth
features of normal MECs, as we hypothesized on the
basis of clinical data. MCF10A-SOX11 cells are not
more clonogenic, but form more clones with basal/
myoepithelial morphology, than MCF10A-control cells
(Figure 2C, D). MCF10A-SOX11 cells have greater
mammosphere-forming capacity and produce mam-
mospheres with phenotypes that are distinguishable
from those of MCF10A-control cells (Figure 2C, D).
CC3 levels were slightly reduced in MCF10A-SOX11
mammospheres as compared with MCF10A-control
mammospheres (Figure 2E). No invasive growth was
observed when MCF10A-SOX11 spheroids were
used in 3D invasion assays (supplementary mate-
rial, Figure S2C). No morphological differences were
observed between MCF10A-SOX11 spheroids and
MCF10A-LacZ control spheroids grown without
hydrogel (supplementary material, Figure S2D).
Effect of SOX11 levels on DCIS
We stably transduced SOX11 into DCIS.com cells to
study the effects of expressing SOX11 in a cell line that
is used to model DCIS formation and its progression
to invasive disease (supplementary material, Figure
S3). DCIS-SOX11 spheroids appeared similar in mor-
phology to DCIS-control spheroids when they formed
(day 0), but showed a slight reduction in volume after
14 days (Figure 3A). Cell growth was slightly reduced
in DCIS-SOX11 cells as compared with controls
(Figure 3B). We assessed CC3 levels as a possible mech-
anism underlying the more compact and less necrotic
phenotype observed in DCIS-SOX11 spheroids.
We detected lower levels of caspase-3 activity in
DCIS-SOX11 spheroids than in DCIS-control spheroids
(Figure 3C, D). By FACS analysis, we detected over
two-fold higher ALDH activity in DCIS-SOX11
cell populations than in controls (Figure 3E). The
CD44+/CD24– population was increased 1.5-fold in
DCIS-SOX11 cells (Figure 3F). A 7.7-fold increase in
the frequency of CD44+/CD24–/ALDH+ cells was
detected among DCIS-SOX11 cells as compared with
control cell populations; no significant change was
detected in the frequency of CD44+/CD24+/ALDH+
cells (Figure 3G; supplementary material, Figure S4).
EpCAM–/CD49f+/ALDH+ cells were detected at
a higher frequency among DCIS-SOX11 cells than
among controls (Figure 3H).
© 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2017
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Figure 1. Expression of SOX11 in postnatal mammary epithelial cells alters progenitor cell populations. (A) SOX11 expression was not
detected in normal mature breast tissue. Scale bar: 200 μm. (B) SOX11 was expressed in some basal-like breast cancer and HER2+ cell
lines, but not in MCF10A or DCIS.com cells. (C) Western blot of MCF10A-LacZ control and MCF10A-SOX11 cells. SOX11 levels (indicated
by numerical values) were measured by densitometry, and normalized by dividing by the tubulin values. (D) Immunofluorescence staining
of MCF10A-LacZ control and MCF10A-SOX11 cells with DAPI (blue in inset) and SOX11 (white). Scale bar: 50 μm. (E) Representative FACS
analysis of EpCAM/CD49f-sorted MCF10A-control and MCF10A-SOX11 cell populations. Experiments were performed five times. The average
percentage of EpCAM–/CD49f + cells in each population is shown [median ± standard deviation (SD)]. Student’s t-test was performed. (F)
ALDH activity levels in MCF10A-control and MCF10A-SOX11 cells were detected with the Aldefluor assay. Cells were stained and sorted with
CD49f and EpCAM antibodies, and ALDH activity was measured with the Aldefluor kit. Representative ALDH activities after FACS analysis
in EpCAM–/CD49f + MCF10A-control and MCF10A-SOX11 cell populations are shown. +DEAB plots display the negative control; cells
incubated with diethylaminobenzaldehyde (DEAB), the specific inhibitor of ALDH, were used to establish the baseline fluorescence of these
cells. Experiments were performed four times, and Student’s t-test was performed. The frequency of EpCAM–/CD49f + basal-like ALDH+
cells (left graph) and EpCAM–/CD49f+/ALDH+ cells (right graph) in MCF10A-SOX11 as compared with MCF10A-LacZ control populations
are shown. Error bars represent SD.
© 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2017
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Figure 2. Effect of SOX11 expression on postnatal mammary epithelial cell growth, morphogenesis, and clonogenicity. (A) CellTiter-Glo
assay results for MCF10A-LacZ-control and MCF10A-SOX11 cells. Experiments were performed three times (n = 18 in each sample), and
ANOVA and multiple comparisons were used for statistical analysis. The values obtained in each time point [counts per second (CPS)] were
normalized by dividing by the value obtained at day 0 in each population. P < 0.05 for MCF10A-SOX11 versus MCF10A-LacZ; P < 0.0001
for MCF10A-SOX11 versus MCF10A-luc. (B) Representative images of MCF10A-LacZ control and MCF10A-SOX11 mammospheres that were
grown from spheroids formed in low-attachment plates, 10 and 14 days after addition of BME. Experiments were performed three times.
Scale bar: 200 μm. (C) Quantification of clonogenicity and mammosphere-initiating capacity. Left: percentage of MCF10A cell populations
plated in two-dimensional (2D) culture that form colonies. Centre: percentage of colonies with basal or myoepithelial morphology of the
total cell number plated in 2D culture. Right: percentage of mammospheres formed from cells in 3D culture. All experiments were performed
three times. ***P < 0.001, ***P < 0.0001. (D) Typical morphologies observed for colonies of MCF10A-LacZ and MCF10A-SOX11 cells in (C)
(left) (scale bar: 1 mm) and for mammospheres derived from single MCF10A-LacZ and MCF10A-SOX11 cells embedded in methylcellulose
(right). Single cells proliferated and formed cell clusters with a large central lumen in MCF10A-SOX11 mammospheres. Scale bar: 200 μm.
(E) Quantification of cleaved caspase-3 levels (left) and representative images of MCF10A-luc, MCF10A-LacZ and MCF10A-SOX11 spheroids
5 days after sphere formation. The experiment was performed three times; P < 0.05. Scale bar: 200 μm. All error bars represent standard
deviation. CFU, Counts fluorescence units.
© 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2017
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Figure 3. Effect of SOX11 expression on DCIS cells. (A) Spheroids from DCIS-LacZ and DCIS-SOX11 cells at day 14 grown in BME (top images):
relative growth curves showing area (μm2), volume (μm3) and perimeter (μm) of DCIS-SOX11 spheroids as compared with DCIS-LacZ control
spheroids. Scale bar: 200 μm. (B) CellTiter-Glo assay results of DCIS-LacZ control and DCIS-SOX11 cells. Experiments were performed three
times (n = 56 in each sample), and Student’s t-test was used for statistical analysis. The values obtained in each time point [counts per
second (CPS)] were normalized by dividing by the value obtained at day 0 in each population. P < 0.0001 for the three time points. (C)
Representative images of cleaved caspase-3 activity in spheroids from DCIS-LacZ control and DCIS-SOX11 cells 8 days after spheres had
formed. Scale bar: 200 μm. (D) Relative cleaved caspase-3 activity detected in spheroids from DCIS-SOX11 cells as compared with spheroids
from DCIS-LacZ cells at day 8 [Counts fluorescence units (CFU)]. (E) ALDH activity in DCIS-control versus DCIS-SOX11 populations. (F)
Frequency of CD44+/CD24– cells in DCIS-SOX11 as compared with DCIS-control populations. (G) Frequency of CD44+/CD24–/ALDH+ cells
in DCIS-SOX11 as compared with DCIS-control populations. (H) Frequency of EpCAM–/CD49f+/ALDH+ cells in DCIS-SOX11 as compared
with DCIS-control populations. All error bars represent standard deviation.
© 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2017
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Figure 4. SOX11 increases the invasive activity of DCIS cells in vitro and promotes the growth and progression of DCIS cells in vivo. (A)
Representative images of DCIS-LacZ control and DCIS-SOX11 spheroid invasion in collagen I at day 2. Scale bar: 500 μm. Error bars represent
standard deviation. (B) Area of invasion of DCIS-SOX11 as compared with DCIS-LacZ control spheroids in collagen I at day 2. P = 0.0162.
Experiments were performed three times. (C) Representative images of in situ and microinvasive lesions formed from DCIS-LacZ control
cells that appeared in mice injected intraductally 6–7 weeks after xenografting. Lamin A/C stain detects human cells. Scale bar: 100 μm.
(D) Representative images of in situ lesions, microinvasive lesions and invasive lesions formed from DCIS-SOX11 cells that appeared in mice
injected intraductally 6–7 weeks after xenografting. Lamin A/C stain detects human cells. Scale bar: 100 μm. (E) Results from intraductal
injections of DCIS-LacZ control and DCIS-SOX11 cells; representative images and quantification of in vivo bioluminescence 6–7 weeks after
injection of DCIS-LacZ control and DCIS-SOX11 cells. Results are expressed in photons per second (p/s); P < 0.0001. Each dot represents
the total photon count from each injected mammary gland. Error bars represent standard error of the mean (SEM).
SOX11 promotes invasive growth of DCIS cells in
vitro
Cell migration through collagen was significantly
enhanced in DCIS-SOX11 cells as compared with
control cells in a Transwell assays (supplementary
material, Figure S5A). The results from 3D invasion
assays showed that SOX11 significantly increased inva-
sion of DCIS-spheroids through collagen (Figure 4A, B;
supplementary material, Figure S5B). We measured
levels of melanoma inhibitory activity (MIA), encoded
© 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2017
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by a gene in the PAM50 test, which are characteristically
high in basal-like breast cancer, and are decreased
upon small interfering RNA-mediated knockdown
of SOX11 in breast cancer cells, in a recent study
[25]. MIA is secreted by melanoma cells after their
malignant transformation, and plays a key role in
melanoma progression and invasion. We found that
DCIS-SOX11 cells expressed over four-fold greater
levels of MIA than DCIS-LacZ control cells (supple-
mentary material, Figure S6). Neither MCF10A-LacZ
nor MCF10A-SOX11 cells expressed detectable levels
of MIA. These results show that SOX11 expression can
lead to profound phenotypic changes when expressed
in mature ER–/PR–/HER2– breast cells, but the acqui-
sition of an invasive phenotype is context-dependent.
SOX11 promotes growth and progression of DCIS
cells in vivo
Using the mouse mammary intraductal (MIND)
model developed by Behbod et al. [21], we injected
DCIS-control and DCIS-SOX11 cells into the mammary
ducts of female mice. We collected mammary glands
6–7 weeks later, and sectioned through a subset of them.
Mammary glands from mice injected intraductally with
DCIS-control cells contained in situ lesions and some
microinvasion (Figure 4C). Mammary glands from
mice injected intraductally with DCIS-SOX11 cells
had extensive microinvasion and invasion (Figure 4D;
supplementary material, Figure S7). We detected
significantly more bioluminescence in mice injected
intraductally with DCIS-SOX11 cells 6–7 weeks after
xenografting (Figure 4E). We also collected mam-
mary glands from the same cohort of mice 12 weeks
after xenografting; invasive tumours formed from both
DCIS-control and DCIS-SOX11 cells. Significantly
more bioluminescence was observed in DCIS-SOX11
tumours, and these were larger than DCIS-control
tumours (supplementary material, Figure S7). RNA
sequencing of lesions collected at the microinvasive
stage (6–7 weeks after injection) showed deregu-
lated RNA expression of extracellular matrix (ECM)
components and cell shape regulators, and increased
expression of secreted growth factors and peptides
(Table 1). Invasive tumours collected 12 weeks after
injection of DCIS cells into mammary ducts showed
increased expression of genes encoding signal peptides,
ECM components, and regulators of embryonic organ
morphogenesis (Table 2). Downregulated genes in
the lesions and tumours that formed after intraductal
DCIS injections included those encoding glycoproteins,
endopeptidase inhibitors, and regulators of neuron
projection, apoptosis, and cell adhesion (supplementary
material, Table S4).
We also injected DCIS-control and DCIS-SOX11
cells directly into the mammary fat pads of female
mice. IVIS imaging showed that DCIS-SOX11 cells
had more bioluminescence and greater tumour volume
6 weeks after injection of cells (supplementary mate-
rial, Figure S7). Invasive tumours that formed after
Table 1. Potential downstream SOX11 targets identified by RNA
sequencing of tumours formed after intraductal and fat pad
injections of DCIS-control and DCIS-SOX11 cells; list of the top
upregulated genes in DCIS-SOX11 lesions from samples collected























*Log2FC indicates [log2(DCIS-SOX11) – log2(DCIS-control)].
mammary fat pad injections of DCIS-SOX11 cells
showed elevated expression of genes associated
with organogenesis and developmental processes
(supplementary material, Table S5), with similar gene
signatures to those injected intraductally. A number
of candidate effectors of SOX11 signalling in DCIS
were identified, including ALDH1A1 and HORMAD1,
which have established links to breast cancer. ALDH1
is a marker of normal and malignant human mammary
stem cells and a predictor of poor clinical outcome
[26]. ALDH1A1 isoform expression is a cancer stem
cell marker and predictor of progression and poor
survival [27,28]. Elevated HORMAD1 expression
suppresses RAD51-dependent homologous recombi-
nation and drives the use of alternative forms of DNA
repair [29].
Quantitative polymerase chain reaction (qPCR)
analysis revealed higher levels of SOX11, FHAD1,
HORMAD1 and TFAP2B expression in DCIS-SOX11
than in DCIS-LacZ tumours (Figure 5A). We used IHC
to stain ALDH1A1, and detected ALDH1A1+ cells
in early lesions collected 6–7 weeks after injection of
DCIS-control cells and DCIS-SOX11 cells (Figure 5B).
In tumours formed after injection of DCIS-control cells
into the mammary fat pad, dispersed ALDH1A1+ cells
were detected predominantly in the tumour interior
(Figure 5C). We detected large clusters of ALDH1A1+
cells in the interior portion of the tumour, as well as
at the tumour periphery, in DCIS-SOX11 tumours
(Figure 5C). ALDH1A1+ cells were detected in DCIS
lesions from ER–/SOX11+ DCIS cases (supplementary
material, Figure S8).
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Table 2. Potential downstream SOX11 targets identified by RNA
sequencing of tumours formed after intraductal and fat pad
injections of DCIS-control and DCIS-SOX11 cells; list of the top
upregulated genes in DCIS-SOX11 lesions from all intraductal















































*Log2FC indicates [log2(DCIS-SOX11) – log2(DCIS-control)].
SOX11 is expressed in breast cancers that progress
to form metastases and in preinvasive breast lesions
Higher levels of SOX11 expression are associated with
a worse outcome in patients with lymph node-negative
breast cancer, with an increased likelihood of the disease
progressing to form distant metastases and decreased
overall survival (Figure 6A, B; supplementary material,
Figure S9) [30]. High levels of nuclear SOX11 were
detected by IHC in ER– DCIS lesions as compared with
ER+ DCIS lesions (P = 0.0002, Fisher’s exact test) in
a small cohort of pure DCIS cases (13/22 ER–, six of
17 HER2+, one of 22 ER+, and DCIS and invasive
components of four of six mixed cases) (Figure 6C, D;
supplementary material, Figure S10).
Discussion
We investigated the consequences of expressing SOX11,
an embryonic mammary factor, in normal breast and
DCIS cell lines originating from the MCF10A pro-
gression series. MCF10A and DCIS.com cells do not
express significant levels of SOX11 [31]. Our findings
show that engineering SOX11 expression in MCF10A
cells significantly alters progenitor cell features and
confers distinct traits on mature postnatal MECs.
SOX11 expression results in an expanded basal-like
population. ALDH activity, a marker of human luminal
progenitor cells [32], was increased significantly within
the basal-like population of MCF10A cells. These find-
ings suggest that SOX11 expression in mature MECs
increases the size of a population of cells with features
of both basal and luminal lineages. A large percentage
of prenatal mammary cells express markers associ-
ated with both the basal and luminal lineages in both
mouse and human mammary epithelium [14,33]. An
increased frequency of basal-like clones and increased
mammosphere-forming capacity in MCF10-SOX11
cells are consistent with the finding that ALDH+ cells
from normal breast epithelium have stem cell proper-
ties [26]. MCF10A-SOX11 cells have a slight growth
disadvantage as compared with controls, and do not
show invasive properties. Expression of SOX11 in
normal postnatal MECs alters progenitor cell features
and morphogenesis without promoting invasion.
Expression profiling of the lesions and tumours that
formed after intraductal injection of DCIS.com cells
expressing SOX11 identified a large number of candi-
date downstream effectors, during both the microinva-
sive and invasive growth stages. Many have significant
links to stem cell biology and embryonic developmental
processes. ALDH1A1 plays a role in the proliferation and
differentiation of mammary progenitor cells in the nor-
mal breast; clonogenicity is decreased upon ALDH1A1
knockdown [34]. TFAP2B is thought to stimulate cell
proliferation and suppress terminal differentiation of
specific cell types during embryonic development [35].
Mutations in TFAP2B cause Char syndrome, a disorder
characterized by defective heart, craniofacial and limb
development [36]. Cancer/testis genes are expressed by
germ cells, and are quiescent in somatic cells, but acti-
vated in various cancers. CT46/HORMAD1, a meiotic
gene, is a driver of homologous recombination defi-
ciency in triple-negative breast cancers [29].
Many genes found to be upregulated in DCIS-SOX11
lesions encode ECM components or ECM modulators,
including signal peptides and secreted growth factors.
The ECM is highly modified in cancer, and can drive
disease progression at the primary tumour site or its
metastasis. SOX11 may contribute to the propagation
of invasive phenotypic changes in DCIS.com cells by
© 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2017
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Figure 5. Downstream effectors of SOX11 signalling identified in a mouse model of DCIS that recapitulates human disease. (A) Quantitative
polymerase chain reaction (qPCR) analysis of SOX11 and potential SOX11 downstream effectors, i.e. FHAD1, HORMAD1, and TFAP2B, in
tumour samples; P < 0.0001. Results are expressed as fold change. Error bars represent standard deviation. (B) ALDH1A1 staining of DCIS
lesions that form after mammary intraductal injections of DCIS-LacZ control and DCIS-SOX11 cells. Scale bar: 100 μm. (C) ALDH1A1 staining
of tumours that formed after mammary fat pad injections of DCIS-LacZ control and DCIS-SOX11 cells. Scale bar: 100 μm.
generating ECM cleavage products, including signal
peptides with potential signalling functions and local
release of growth factors. Together, our findings suggest
that breast lesions expressing SOX11 have altered
progenitor/stem cell populations and an increased
propensity for tissue remodelling and invasion.
SOX11 is expressed in a variety of other cancers,
including glioma, lung, mantle cell lymphoma (MCL),
and ovarian and prostate cancer [37,38]. SOX11 is
aberrantly expressed in most aggressive MCLs, and is
considered to be a reliable biomarker in MCL pathology
[39]. SOX11 is most highly expressed in basal-like and
© 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2017
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Figure 6. SOX11, an embryonic mammary epithelial marker, predicts poor clinical outcome in breast cancer patients and is expressed in
preinvasive breast lesions. (A) Disease-free survival (DSS) curves for 1032 breast cancer patients with lymph node-negative disease and with
low and high SOX11 expression from analysis of microarray data from the METABRIC dataset. Expression data were stratified into quartiles
based on SOX11 expression, and the lowest expression quartile (Q1) was treated as the baseline for the subsequent pairwise comparisons
with the remaining quartiles. The statistical significance of pairwise comparisons was assessed with the Wald test. (B) Overall survival
(OS) curves for 1032 breast cancer patients with lymph node-negative disease and with low and high SOX11 expression from analysis of
microarray data from the METABRIC dataset. Expression data were stratified into quartiles based on SOX11 expression, and the lowest
expression quartile (Q1) was treated as the baseline for the subsequent pairwise comparisons with the remaining quartiles. The statistical
significance of pairwise comparisons was assessed with the Wald test. (C and D) Haematoxylin and eosin stain (C) and SOX11 expression
(D) in DCIS lesions. Scale bar: 200 μm. HR, hazard ratio.
HER2+ breast cancers, but further studies are needed to
assess whether it will be a useful biomarker for clinical
use [9,25].
Our results show that the effect of SOX11 expres-
sion in mammary cells from the MCF10A series is
context-dependent. Invasive growth is dramatically
increased in DCIS.com cells engineered to express
SOX11, but not in MCF10A-SOX11 cells. DCIS.com
cells are clonally derived from H-Ras-transformed
MCF10A cells, and it is plausible that, without expres-
sion of a driver of a malignant phenotype such as
HRAS, SOX11 will not promote invasive growth. Three
additional predicted cancer driver mutations (EPHA7,
MAP3K12, and PCSK5) were identified that were
acquired during the transformation of non-malignant
MCF10A cells to malignant DCIS.com cells that could
© 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2017
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also be implicated in the cell-context dependency of
SOX11 in promoting invasion [31].
A recent molecular study of DCIS and early-stage
invasive breast cancers detected high levels of SOX11
expression in samples of pure DCIS and invasive
tumours [40]. High levels of SOX11 expression were
detected predominantly in basal-like and HER2+
lesions. SOX11 is coexpressed among a cluster of
genes that identify a distinct DCIS subgroup with gene
expression characteristics that are more similar to those
of advanced tumours [41]. Functional annotation of
genes expressed within this DCIS subtype showed
enrichment of genes associated with developmental
processes and organ morphogenesis. Using in vitro
and in vivo studies of DCIS.com cells, we showed that
SOX11 promotes cell survival and invasion of DCIS
cells, and increases the size of the ALDH+ popula-
tion, including the CD44+/CD24–/ALDH+ subset.
The CD44+/CD24–/ALDH+ phenotype is thought to
increase tumourigenicity of breast cancer cells [26].
Collectively, these findings support the notion that
DCIS lesions that express SOX11 possess properties
that make them aggressive and cause them to progress
to invasive breast cancer.
Of the ER– DCIS cases that we tested by IHC,
59% were SOX11+. High-level SOX11 expression is
associated with poor overall survival in all breast cancer
patients [9] and a poor outcome in patients with lymph
node-negative disease, a group that normally has a good
predicted outcome. However, the datasets used for the
survival analyses do not represent DCIS. In order to
establish whether SOX11 overexpression in DCIS is
associated with an increased risk of developing invasive
disease, analysis of a large number of pure DCIS sam-
ples with long-term follow-up is required. The Sloane
Project, a UK-wide prospective audit of screen-detected
DCIS (http://www.sloaneproject.co.uk), and LORIS,
a UK phase III trial comparing surgery with active
monitoring for low-risk DCIS, will be useful for eval-
uating the clinical value of SOX11 expression and its
correlation with DCIS progressing to invasive breast
cancer [42].
We have related SOX11 expression to increased
invasive growth and progression of DCIS cells. We
identified potential downstream effectors of SOX11 in
DCIS, which adds new biological information that may
contribute to a better understanding of the pathology
and the identification of suitable treatment options for
patients with breast lesions that express SOX11. SOX11
is a potential biomarker for ER– DCIS that may be at
a higher risk of progression. Further investigations are
needed to determine whether patients with DCIS lesions
expressing SOX11 are more likely to develop invasive
disease.
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